Status:
NOT_YET_RECRUITING
Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer.
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Peritoneal Carcinomatosis
Peritoneal Metastases From Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Colorectal cancer is highly prevalent in France, ranking second among women and third among men. Its primary metastatic sites include the liver, lungs, and peritoneum. For peritoneal metastases, when ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Common criteria:
- Male/female over 18 years of age.
- Weight ≥ 55 kg at inclusion.
- Signature of a free and informed consent form.
- Specific criteria:
- Group 1:
- Peritoneal metastases colorectal cancer histologically proven
- Synchronous or metachronous peritoneal metastases.
- Patients eligible for initial cytoreduction surgery.
- Non mucinous tumor (mucinous cells contingent \<30%).
- Group 2:
- Colorectal cancer
- Group 3:
- Non-oncological chronic inflammatory diseases
- Group 4:
- Non-oncological chronic inflammatory diseases : parietal repairs, elective sigmoidectomy for diverticulosis
- Group 5:
- Abdominal sepsis conditions: peritonitis due to digestive perforation in non-oncological pathology, non-perforated appendicitis, cholecystitis.
- Non inclusion Criteria:
- Patient with an active cancer (excluding colorectal cancer).
- Person with a progressive autoimmune disease.
Exclusion
Key Trial Info
Start Date :
April 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 30 2026
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT06929013
Start Date
April 15 2025
End Date
May 30 2026
Last Update
April 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Lyon Sud
Pierre-Bénite, France, 69310